Abstract
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has antidepressant and antisuicidal effects, as shown by multiple studies done over the past two decades, that can be used effectively in the management of treatment-resistant depression (TRD). The United States Food and Drug Administration has approved intranasal (S)-ketamine in combination with an oral antidepressant for TRD. Although research is promising with respect to ketamine's effect on depression and suicidality, the need for in-office administration and treatment monitoring limits the accessibility of treatment. Significant concerns remain regarding the risks of treatment and its abuse potential. Nonetheless, its potential efficacy in TRD and suicidality makes ketamine an effective treatment modality for this patient population. [ Psychiatr Ann . 2024;54(6):e170–e176.]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
